Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways
Xinmei Liao, Xiaoqing Qian, Zimu Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Liquid–liquid phase separation in tumor biology
Xuhui Tong, Rong Tang, Jin Xu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 136
The Common Hallmarks of Aging, Circadian Rhythms and Cancer: Implications for Therapeutic Strategies
Jie Wang, Fanglin Shao, Qingxin Yu, et al.
Research (2025) Vol. 8
Open Access | Times Cited: 2
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
Ryan Finnegan, Ahmed M. Elshazly, Nipa Patel, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 19
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer
Jessy M. Stafford, Michael D. Wyatt, Campbell McInnes
Expert Opinion on Drug Discovery (2022) Vol. 18, Iss. 1, pp. 65-81
Open Access | Times Cited: 23
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Xuelian Liu, Anjin Wang, Yuying Shi, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1217-1217
Open Access | Times Cited: 13
Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells
Thamir M. Ismail, Rachel G. Crick, Min Du, et al.
Biomolecules (2023) Vol. 13, Iss. 7, pp. 1099-1099
Open Access | Times Cited: 11
Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple Negative Breast Cancer Treatment
Hongye He, Feng Li, Rui Tang, et al.
Biomaterials Research (2024) Vol. 2024
Open Access | Times Cited: 4
BRD4 promotes hepatic stellate cells activation and hepatic fibrosis via mediating P300/H3K27ac/PLK1 axis
Miao Cheng, Juanjuan Li, Xue-ni Niu, et al.
Biochemical Pharmacology (2023) Vol. 210, pp. 115497-115497
Closed Access | Times Cited: 9
Unlocking the Potential of Camel Milk-Derived Exosomes as Novel Delivery Systems: Enhanced Bioavailability of ARV-825 PROTAC for Cancer Therapy
Aakash Nathani, Mounika Aare, Li Sun, et al.
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1070-1070
Open Access | Times Cited: 3
PROTACs in gastrointestinal cancers
Yu Chen, Qingfan Yang, Jinrun Xu, et al.
Molecular Therapy — Oncolytics (2022) Vol. 27, pp. 204-223
Open Access | Times Cited: 14
BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia
Xu Sang, Yongping Zhang, Fang Fang, et al.
Journal of Immunology Research (2022) Vol. 2022, pp. 1-18
Open Access | Times Cited: 13
BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer
Ahmed M. Elshazly, Melanie M. Sinanian, Victoria Neely, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4066-4066
Open Access | Times Cited: 7
Characterization of tumor endothelial cells (TEC) in gastric cancer and development of a TEC-based risk signature using single-cell RNA-seq and bulk RNA-seq data
Meng Fan, Xiaofei Xu, Yu Hu
Aging (2024) Vol. 16, Iss. 12, pp. 10252-10270
Open Access | Times Cited: 2
Recent advances in dual PROTACs degrader strategies for disease treatment
Jianyu Liu, Yanzhuo Liu, Jiao Tang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116901-116901
Closed Access | Times Cited: 2
Epigenetic signatures in gastric cancer: current knowledge and future perspectives
Fatma Söğütlü, Mert Pekerbaş, Çığır Biray Avci
Expert Review of Molecular Diagnostics (2022) Vol. 22, Iss. 12, pp. 1063-1075
Closed Access | Times Cited: 9
UPS: Opportunities and challenges for gastric cancer treatment
Hang Yang, Huihan Ai, Jialin Zhang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Bromodomain and Extra-Terminal Domain Protein 2in Multiple Human Diseases
Yikang Ji, Wantao Chen, Xu Wang
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 389, Iss. 3, pp. 277-288
Open Access
Optimization of the Procedure for Gram Scale Synthesis of Silicon Rhodamine and its Application in Labeling BRD4 Kinase Inhibitor
Yanan Zhou, Tao Bi, Raoqiong Wang, et al.
Journal of Analysis and Testing (2024)
Closed Access
ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4
Yang Liu, Jing Yue, Xia Xia, et al.
Journal of Oncology (2023) Vol. 2023, pp. 1-12
Open Access | Times Cited: 1
Inhibition of BRD4 enhanced the tumor suppression effect of dasatinib in gastric cancer
Hao Shen, Xuefei Hu, Xinrui Yang, et al.
Medical Oncology (2022) Vol. 40, Iss. 1
Open Access | Times Cited: 2
BRD4 PROTAC Degradation Agent GNE-987 Inhibits Acute Myeloid Leukemia by Targeting Super Enhancers
Xu Sang, Yongping Zhang, Fang Fang, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 2
Procedure Optimization for Gram Scale Synthesis of Silicon Rhodamine and its Use in Labeling of Protein Kinase Inhibitor
Tao Bi, Yanan Zhou, Pan Liang, et al.
(2023)
Closed Access
Prognostic clinical phenotypes associated with tumor stemness in the immune microenvironment of T-cell exhaustion for hepatocellular carcinoma
Genhao Zhang
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access
Potential effects of POLR2H and DYNC1I2 on the immunity and prognosis of neuroblastoma
Yingxuan Ma, Li Lu, Zhi Li, et al.
Research Square (Research Square) (2022)
Open Access
Page 1 - Next Page

Scroll to top